Abstract
Long-lasting results achieved in 54 patients with aggressive non-Hodgkin lymphoma treated with Pro-MACE-CytaBOM regimen were evaluated. Twenty-four out of 54 (45%) patients achieved a complete remission and 13 of them are still in continuous remission with a median survival of 53.5 months. Interestingly, in 16 patients with intermediate grade histology we obtained an overall response rate of 100%.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bleomycin / administration & dosage
-
Bleomycin / adverse effects
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Cytarabine / administration & dosage
-
Cytarabine / adverse effects
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Etoposide / administration & dosage
-
Etoposide / adverse effects
-
Female
-
Follow-Up Studies
-
Humans
-
Lymphoma, Non-Hodgkin / drug therapy*
-
Lymphoma, Non-Hodgkin / mortality
-
Male
-
Methotrexate / administration & dosage
-
Methotrexate / adverse effects
-
Middle Aged
-
Neutropenia / chemically induced
-
Prednisone / administration & dosage
-
Prednisone / adverse effects
-
Survival Rate
-
Treatment Outcome
-
Vincristine / administration & dosage
-
Vincristine / adverse effects
Substances
-
Cytarabine
-
Bleomycin
-
Vincristine
-
Etoposide
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone
-
Methotrexate